

EN
E-001420/2025
Answer given by Mr Várhelyi
on behalf of the European Commission
(2.7.2025)

The Commission supports Member States in reducing the burden of non-communicable diseases (NCDs), including hyperemesis gravidarum (HG), under the framework of the ‘Healthier Together’ EU NCDs initiative¹. Financial support from the EU4Health programme² is provided for actions under the initiative, which must include a health equity dimension and address different groups’ needs, including women.

The Commission also supports the collection and transfer of best and promising practices among Member States via the EU Best Practice Portal on Public Health³.

The Public Health Expert Group⁴ assists the Commission, including on the preparation of policy and legislative initiatives and activities addressing major public health challenges.

The proposed reform of the EU pharmaceutical legislation⁵, currently under negotiation, promotes the development of innovative medicines including for unmet medical needs. Measures provide dedicated regulatory support⁶ for those medicines as well as targeted incentives.

The EU is at the forefront of supporting research and innovation (R&I) to improve and protect health and well-being of citizens. Over EUR 1.3 billion have been invested in more than 700 R&I projects related to women’s health, including gynaecological-related diseases, through the EU’s R&I framework programmes, Horizon 2020⁷ and Horizon Europe⁸.

Specific funding for R&I into HG under Horizon Europe is not currently planned. Horizon Europe, however, offers a variety of funding opportunities, including calls for collaborative proposals under its cluster 1 ‘Health’ Work Programme 2025.⁹ There is more information on opportunities for further research on women’s health and gynaecological diseases¹⁰.

¹ https://health.ec.europa.eu/non-communicable-diseases/healthier-together-eu-non-communicable-diseases-initiative_en.

² https://commission.europa.eu/funding-tenders/find-funding/eu-funding-programmes/eu4health_en.

³ <https://webgate.ec.europa.eu/dyna/bp-portal/>.

⁴ https://health.ec.europa.eu/non-communicable-diseases/expert-group-public-health_en.

⁵ COM/2023/193 final and COM/2023/192 final.

⁶ Regulatory support is provided from the European Medicines Agency.

⁷ https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-2020_en.

⁸ https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en.

⁹ This includes the recently opened call topic on tackling high burden for patients and under-researched medical conditions <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-DISEASE-07>.

¹⁰ It can be found through the EU Funding and Tenders Portal <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>.